Loading…
Calidi Biotherapeutics, Inc. is projected to rise to $0.1501 by 2027, a +7% move from its current price of $0.1409. CLDI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.135 | $0.1409 | $0.1471 | -0.01% |
| Jul 15 | $0.1326 | $0.1409 | $0.1497 | -0.02% |
| Jul 16 | $0.1307 | $0.1409 | $0.1518 | -0.03% |
| Jul 17 | $0.1292 | $0.1408 | $0.1535 | -0.04% |
| Jul 18 | $0.1279 | $0.1408 | $0.1551 | -0.05% |
| Jul 19 | $0.1267 | $0.1408 | $0.1565 | -0.06% |
| Jul 20 | $0.1257 | $0.1408 | $0.1578 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.1257 | $0.1408 | $0.1578 | -0.07% |
| Week 2 | $0.1198 | $0.1407 | $0.1653 | -0.13% |
| Week 3 | $0.1154 | $0.1406 | $0.1713 | -0.20% |
| Week 4 | $0.1119 | $0.1405 | $0.1765 | -0.26% |
| Week 5 | $0.1089 | $0.1404 | $0.1812 | -0.33% |
| Week 6 | $0.1062 | $0.1403 | $0.1855 | -0.39% |
| Week 7 | $0.1038 | $0.1403 | $0.1896 | -0.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease.
It operates in the Healthcare category and has a portfolio including CLD-101, CLD-201, CLD-401, and oncolytic virus platforms NeuroNova and SuperNova. CLD-101 is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 is for solid tumors such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 is for the treatment of metastatic solid tumors.
Calidi Biotherapeutics was founded in 2014 and is headquartered in San Diego, California.
Calidi Biotherapeutics, Inc. (CLDI) is a biotechnology company in the Healthcare sector. The stock trades at $0.1439 per share with a market cap of $2.78M.
Its market rank is 5444, reflecting a relatively small-cap profile within the market. The current price and market position are complemented by a year-by-year forecast that shows a path from the current level toward higher averages in later years, including an average of $0.5264 by 2050 and a max of $1.19 in that year.
The forecast horizon spans 2026 through 2050, with 2026 avg $0.1439 and 2050 avg $0.5264, and an overall progression toward higher values in later years. ROI figures range from 0% in 2026 to 265.8% in 2050, with sentiment shifting to BULLISH in several later years.
A major floor 23.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 34.8% above — a clean break opens room to run.
A major ceiling 464.2% above — clearing it would confirm fresh momentum.
Key CLDI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLDI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.1454 | Sell | $0.1462 | Sell |
| MA 10 | $0.1528 | Sell | $0.1501 | Sell |
| MA 20 | $0.1558 | Sell | $0.1569 | Sell |
| MA 50 | $0.177 | Sell | $0.2014 | Sell |
| MA 100 | $0.2917 | Sell | $0.4229 | Sell |
| MA 200 | $0.8138 | Sell | $2.89 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.37 | Neutral |
| Stoch RSI (14) | 12.87 | Buy |
| CCI (20) | -140.55 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -9.62 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.79 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 26.33 | Buy |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.14 | Sell |
| ADX (14) | 21.77 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40.
The short-term trend shows the stock trading around key levels, with SMA50 at $0.1821 and SMA200 at $0.8353. Support sits at $0.144 and resistance at $0.191, indicating a narrow trading band near the current price.
The 30-day range runs from $0.108 to $0.1918, outlining the near-term volatility range as traders assess upside potential versus downside risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.1409 | $0.1409 | $0.1749 | 0% | Neutral | |
| $0.1131 | $0.1501 | $0.214 | +7% | Neutral | |
| $0.1116 | $0.1552 | $0.2335 | +10% | Neutral | |
| $0.1319 | $0.1908 | $0.2994 | +35% | Bullish | |
| $0.1344 | $0.2015 | $0.3272 | +43% | Bullish | |
| $0.1073 | $0.1662 | $0.2781 | +18% | Neutral | |
| $0.1073 | $0.1714 | $0.2945 | +22% | Bullish | |
| $0.1029 | $0.1694 | $0.2981 | +20% | Bullish | |
| $0.1018 | $0.1723 | $0.3099 | +22% | Bullish | |
| $0.1308 | $0.2276 | $0.4176 | +62% | Bullish | |
| $0.1107 | $0.2192 | $0.4373 | +56% | Bullish | |
| $0.2303 | $0.5118 | $1.15 | +263% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.1409 | $0.1409 | $0.1627 | +0.00% |
| August 2026 | $0.1106 | $0.1325 | $0.1646 | -5.94% |
| September 2026 | $0.1152 | $0.1397 | $0.1765 | +5.41% |
| October 2026 | $0.1127 | $0.1379 | $0.1767 | -1.27% |
| November 2026 | $0.106 | $0.1309 | $0.1697 | -5.11% |
| December 2026 | $0.1073 | $0.1334 | $0.1749 | +1.96% |
Click any year to see its month-by-month CLDI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Calidi Biotherapeutics, Inc.'s 2026 outlook centres on $0.1409, within a $0.1409 to $0.1749 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CLDI could reach as high as $0.214, with a base case around $0.1501 and support toward $0.1131 — roughly +7% from $0.1409. Price action looks broadly range-bound.
Expect CLDI to range from $0.1116 to $0.2335 through 2028. The $0.1552 average target implies a +10% move from current prices. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CLDI price prediction for 2029 points to an average of $0.1908 (low $0.1319, high $0.2994) — a potential gain of +35% on today's $0.1409. Momentum favours further upside here.
In 2030, CLDI is projected to trade between $0.1344 and $0.3272, averaging $0.2015 — a potential gain of +43% from today's $0.1409. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Calidi Biotherapeutics, Inc.'s 2031 outlook centres on $0.1662, within a $0.1073 to $0.2781 range. That is -17% versus the projected 2030 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2032, CLDI could reach as high as $0.2945, with a base case around $0.1714 and support toward $0.1073 — roughly +22% from $0.1409. Buyers look set to stay in control over this stretch.
Expect CLDI to range from $0.1029 to $0.2981 through 2033. The $0.1694 average target implies a +20% move from current prices. That is -1% versus the projected 2032 average. Momentum favours further upside here.
The CLDI price prediction for 2034 points to an average of $0.1723 (low $0.1018, high $0.3099) — a potential gain of +22% on today's $0.1409. Buyers look set to stay in control over this stretch.
In 2035, CLDI is projected to trade between $0.1308 and $0.4176, averaging $0.2276 — a potential gain of +62% from today's $0.1409. That is up +32% on the projected 2034 average. Momentum favours further upside here.
Calidi Biotherapeutics, Inc.'s 2040 outlook centres on $0.2192, within a $0.1107 to $0.4373 range. That is -4% versus the projected 2035 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CLDI could reach as high as $1.15, with a base case around $0.5118 and support toward $0.2303 — roughly +263% from $0.1409. Momentum favours further upside here.
Investing $1,000 in CLDI today (≈ 7,097.232079 CLDI) could be worth
$3,632.71
+$2,632.71 (+263%) by 2050 · US Dollar
Based on the average projected CLDI price of $0.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLDIwould be worth at today's price.
$1,000 invested in CLDI on Jul 10, 2025 (≈ 83.500335 CLDI) would be worth
$11.77
-$988.23 (-98.8%) today · 0.01× · US Dollar
Based on a CLDI entry price of $11.98 vs. today's $0.1409.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.149 | $945.64 | -5.4% |
| 1 month ago | $0.169 | $833.73 | -16.6% |
| 3 months ago | $0.257 | $548.25 | -45.2% |
| 6 months ago | $1.12 | $125.8 | -87.4% |
| 1 year ago | $11.98 | $11.77 | -98.8% |
| All time (4.7y) ago | $1,173.6 | $0.12 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLDI forecast.
Our base-case forecast reaches $0.28 around 2050.
Implied market cap at $0.28: $5.41M
The multi-year forecast provides year-by-year numbers that outline a path of gradual appreciation. In 2026, min $0.1439, avg $0.1439, max $0.18, ROI 0, sentiment NEUTRAL.
In 2027 the range shows min $0.1147, avg $0.1526, max $0.2182, ROI 6, sentiment NEUTRAL, followed by 2028 with min $0.1138, avg $0.1587, max $0.2397, ROI 10.3, sentiment NEUTRAL.
The trajectory strengthens into 2029 with min $0.1355, avg $0.1968, max $0.3098, ROI 36.7, sentiment BULLISH, and 2030 at min $0.1366, avg $0.2057, max $0.3354, ROI 43, sentiment BULLISH. From 2031 onward, the forecast continues to show growth potential (e.g., 2031 min $0.1084, avg $0.1687, max $0.2834, ROI 17.2, NEUTRAL; 2032 min $0.1097, avg $0.1762, max $0.3041, ROI 22.5, BULLISH; 2033 min $0.1044, avg $0.1728, max $0.3055, ROI 20.1, BULLISH; 2034 min $0.1029, avg $0.1753, max $0.3167, ROI 21.8, BULLISH).
The outlook remains bullish into the mid-2020s with 2035 showing min $0.1338, avg $0.2344, max $0.4323, ROI 62.9, sentiment BULLISH, and 2040 at min $0.1116, avg $0.2231, max $0.4473, ROI 55, sentiment BULLISH. By 2050, the forecast envisions min $0.2369, avg $0.5264, max $1.19, ROI 265.8, sentiment BULLISH. These figures illustrate an upside potential across the horizon, tempered by the inherent uncertainty of small-cap biotech equities.
Tap a question to reveal the answer.
2030 min $0.1366, avg $0.2057, max $0.3354; ROI 43; sentiment BULLISH.
Forecasts show a mix of Neutral and Bullish sentiment over the horizon, with ROI 0% in 2026, 36.7% in 2029, 43% in 2030, 62.9% in 2035, and 265.8% in 2050. These are estimates, not guarantees, and subject to market conditions.
2035 max $0.4323, so the 2035 forecast does not reach $0.50; by contrast, the 2050 max is $1.19, indicating higher upside later in the horizon.
Current price $0.1439; market cap $2.78M.
30-day range low $0.108, high $0.1918; RSI14 40; annualizedVolatilityPct 80.
Calidi Biotherapeutics, Inc. Community Discussion
0Share your Calidi Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.